Performance evaluation of the Aptima HIV-1 RNA Quant assay on the Panther system using the standard and dilution protocols

•A modified Aptima HIV-1 Quant protocol can quantify RNA using 100 μL of plasma.•The standard and modified protocols had high agreement above 50 copies/mL.•Using microtainers for blood collection could expand access to treatment and care. Currently, FDA-approved HIV-1 viral load (VL) assays use veni...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical virology 2020-08, Vol.129, p.104479-104479, Article 104479
Hauptverfasser: Rossetti, Rebecca, Smith, Tara, Luo, Wei, Taussig, Jennifer, Valentine-Graves, Mariah, Sullivan, Patrick, Ingersoll, Jessica M., Kraft, Colleen S., Ethridge, Steve, Wesolowski, Laura, Delaney, Kevin P., Owen, S. Michele, Johnson, Jeffrey A., Masciotra, Silvina
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•A modified Aptima HIV-1 Quant protocol can quantify RNA using 100 μL of plasma.•The standard and modified protocols had high agreement above 50 copies/mL.•Using microtainers for blood collection could expand access to treatment and care. Currently, FDA-approved HIV-1 viral load (VL) assays use venipuncture-derived plasma. The Hologic Panther system uses 0.7 mL total volume for the Aptima HIV-1 Quant Assay standard (APT-Quant-std) and dilution (APT-Quant-dil) protocols. However, smaller plasma volumes from fingerstick whole blood (FSB) collected in EDTA-microtainer tubes (MCT) could provide an easier sample collection method for HIV-1 VL testing. To evaluate the performance of the APT-Quant-std compared to the Roche CAP/CTM and Abbott m2000RT VL assays and an alternative APTQuant 1:7 dilution protocol, the latter using 100 μL of MCT-derived plasma from FSB. Linearity was determined using commercial HIV-1 RNA plasma controls. Dilutions ranging 1.56–2.95 log10 copies/mL were prepared to determine the APT-Quant-dil Limit of Quantitation (LOQ) using Probit analysis. Specificity of APT-Quant-std was calculated using 326 HIVnegative samples. To evaluate agreement, 329 plasma specimens were tested with APT-Quant-std, CAP/CTM, and m2000RT. Forty-seven matched venipuncture and MCT-derived plasma specimens were tested with APT-Quant-std and APT-Quant-dil. Among the RNA controls, specificity was 99.69 % for APT-Quant-std. The R2 values were 0.988 (APT-Quant-std/CAP/CTM), 0.980 (APT-Quant-std/ m2000RT), and 0.997 (APT-Quant-std/APT-Quant-dil). The APT-Quant-dil LOQ was estimated at 2.7 log10 copies/mL (500 copies/mL) (95 %CI 2.62–2.87). At 2.3 log10 copies/mL (200 copies/mL), the overall agreement was 91.0 % for APT-Quant-std/CAP/CTM, 85.7 % for APT-Quant-std/m2000RT, and 82.9 % for APT-Quant-std/APT-Quant-dil. Quantified APT-Quant-std results were on average 0.2 log10 copies/mL higher than CAP/CTM and m2000RT and 0.14 log10 copies/mL higher than APT-Quant-dil. APT-Quant showed similar performance compared to the CAP/CTM and m2000RT assays and remains sensitive and accurate using the dilution protocol.
ISSN:1386-6532
1873-5967
DOI:10.1016/j.jcv.2020.104479